78 results match your criteria: "University of Oklahoma HSC[Affiliation]"
Clin Auton Res
December 2023
Cardiovascular Section, Department of Internal Medicine, Heart Rhythm Institute, University of Oklahoma Health Sciences Center, 800 SL Young Blvd, COM 5400, Oklahoma City, OK, 73104, USA.
Purpose: Acute decompensated heart failure (ADHF) is associated with inflammation, oxidative stress, and excess sympathetic drive. It is unknown whether neuromodulation would improve inflammation and oxidative stress in acute heart failure. We, therefore, performed this proof-of-concept study to evaluate the effects of neuromodulation using noninvasive low-level tragus stimulation on inflammation and oxidative stress in ADHF.
View Article and Find Full Text PDFFront Cell Neurosci
September 2023
Department of Neuropathology, University Medicine Göttingen, Georg-August University Göttingen, Göttingen, Germany.
Next to acute sickness behavior, septic encephalopathy is the most frequent involvement of the brain during infection. It is characterized by a cross-talk of pro-inflammatory cells across the blood-brain barrier, by microglial activation and leukocyte migration, but not by the entry of infecting organisms into the brain tissue. Septic encephalopathy is very frequent in older persons because of their limited cognitive reserve.
View Article and Find Full Text PDFGynecol Oncol Rep
December 2022
Stephenson Cancer Center at the University of Oklahoma HSC, Oklahoma, City, OK, USA.
Purpose: Contemporary, real-world data on eligible patients receiving treatment following progression on first-line (1L) recurrent or metastatic cervical cancer (r/mCC) therapy are needed to inform treatment algorithms and identify potential gaps in the r/mCC care continuum.
Methods: This study estimated the prevalence and predictors of second-line (2L) r/mCC therapy among 1L-treated patients using the 2015-2020 IBM MarketScan® commercial claims database. Women ≥ 18 years diagnosed with cervical cancer and treated with first-line systemic therapies were identified and followed for 12 months from their 1L therapy end date.
Gynecol Oncol
February 2023
Georgia Institute of Technology, Department of Industrial and Systems Engineering, Atlanta, GA, USA; Emory School of Medicine, Atlanta, GA, USA. Electronic address:
Objective: Cervical cancer (CC) disproportionately affects women based on socioeconomic status and racial/ethnic background. There is limited research in quantifying and visualizing whether substantial geographical disparities in the US exist with respect to CC burden, and especially with respect to recurrent or metastatic CC (r/mCC) disease burden. Identifying regions with higher r/mCC burden may help inform effective healthcare resource allocation and navigating patients to appropriate care.
View Article and Find Full Text PDFLeuk Lymphoma
February 2023
Duke University Medical Center, Duke Cancer Institute, Durham, NC, USA.
Gynecol Oncol Rep
December 2022
Stephenson Cancer Center at the University of Oklahoma HSC, Oklahoma, City, OK, USA.
Purpose: Contemporary, real-world data on eligible patients receiving treatment following progression on first-line (1L) recurrent or metastatic cervical cancer (r/mCC) therapy are needed to inform treatment algorithms and identify potential gaps in the r/mCC care continuum.
Methods: This study estimated the prevalence and predictors of second-line (2L) r/mCC therapy among 1L-treated patients using the 2015-2020 IBM MarketScan® commercial claims database. Women ≥ 18 years diagnosed with cervical cancer and treated with first-line systemic therapies were identified and followed for 12 months from their 1L therapy end date.
Nutr Cancer
February 2023
Stephenson Cancer Center at the University of Oklahoma HSC, Oklahoma City, Oklahoma.
This study sought to describe and relate the factors associated with complications and delays in adjuvant chemotherapy in patients with ovarian cancer treated with primary cytoreductive surgery. Serum from patients diagnosed with ovarian cancer scheduled for primary cytoreductive surgery were analyzed for prealbumin, 25-OH Vitamin D, intracellular adhesion molecule 1 (ICAM-1), interleukin 6 (IL-6), interleukin 8 (IL-8), monocyte chemoattractant protein 1 (MCP-1), monocyte chemoattractant protein 2 (MCP-2), macrophage derived chemokine (MDC). Postoperative complications were identified using common terminology criteria for adverse events 4.
View Article and Find Full Text PDFCurr Oncol Rep
December 2022
Stephenson Cancer Center, University of Oklahoma HSC, 800 NE 10th St, Suite 5050, Oklahoma City, OK, 73104, USA.
Purpose Of Review: This review will focus on the most common mechanisms for poly (ADP-ribose) polymerase inhibitors' (PARPi) resistance and the main strategies for overcoming acquired or de novo PARPi resistance.
Recent Findings: Initial approvals for PARPi as part of treatment for advanced epithelial ovarian cancer (EOC) started in 2014 with patient with recurrent cancer characterized by BRCA mutations in the 3rd and 4th line and now have approvals for front-line maintenance in both the BRCA mutated and BRCAwt populations. As with all therapies, patients will eventually develop resistance to treatment.
J Clin Oncol
May 2022
University of Arizona College of Medicine, Creighton University School of Medicine, Virginia G. Piper Cancer Center, HonorHealth Research Institute, Phoenix, AZ.
Radiol Case Rep
May 2022
Department of Interventional Radiology, Foothills Medical Centre, Calgary, Canada.
Coronary subclavian steal syndrome is an uncommon complication occurring in patients with coronary artery bypass graft (CABG). We describe a case of a 69-year-old male with a remote history of CABG who presented with exertional left arm pain and angina. Computed Tomographic Angiography of the chest demonstrated a severe left proximal subclavian artery stenosis.
View Article and Find Full Text PDFAnn Oncol
March 2022
Department of Gynecology & Gynecologic Oncology, Evangelische Kliniken Essen Mitte (KEM), Essen, Germany.
J Ultrason
November 2021
Allied Health, University of Oklahoma HSC, United States.
Currently, the impact of abdominal aortic aneurysm may be changing despite the aging population, but may be ambiguous given the decline in smoking, the use of screening methods, and integration of non-surgical treatment. This review aimed to assess the most common currently used non-invasive methods to identify abdominal aortic aneurysm, namely ultrasound and computed tomography. PRISMA guidelines were utilized to retrieve original articles from the past five years.
View Article and Find Full Text PDFCancer J
February 2022
NYU Langone Health, Perlmutter Cancer Center, New York University School of Medicine, New York, NY.
The emergence of clinical trial data for poly(ADP-ribose) polymerase inhibitors (PARPi), in BRCA-associated ovarian cancer (epithelial ovarian cancer [EOC]) in 2009 (Lancet 2010;376:245-251) unleashed a rapid series of additional asset development and clinical trial activation across all lines of EOC treatment, ultimately leading to 8 new approvals of 3 different PARPi in EOC since 2014. Monotherapy iPARPi were approved as frontline maintenance treatment for all patients with EOC who respond to platinum-based chemotherapy irrespective of biomarker (niraparib) and for BRCA-associated cancers (olaparib) (https://www.azpicentral.
View Article and Find Full Text PDFNutr Cancer
July 2022
Center for Cancer Prevention and Drug Development, Hem-Onc, Department of Medicine, Stephenson Cancer Center, University of Oklahoma HSC, Oklahoma City, Oklahoma, USA.
J Pediatr Urol
December 2021
Division of Pediatric Urology, Department of Urology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Introduction: Filum section (FS) has been used to treat tethered cord syndrome (on MRI or occult) in pediatric patients with refractory dysfunctional voiding (DV). While controversial, some groups have previously reported significant improvement in patients' symptoms after FS, even in the presence of a normal preoperative spinal MRI. Until recently, it was our practice to refer patients with DV to pediatric neurosurgery for evaluation, MRI, and possible FS.
View Article and Find Full Text PDFClin Cancer Res
January 2022
Memorial Sloan Kettering Cancer Center, New York, New York.
Purpose: This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer.
Patients And Methods: Women with histologically or cytologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancer with measurable disease were enrolled between January 2015 and January 2018 in this open-label, four-arm, multicenter, phase II study. Patients received adavosertib (oral capsules, 2 days on/5 days off or 3 days on/4 days off) in six cohorts from 175 mg once daily to 225 mg twice daily combined with gemcitabine, paclitaxel, carboplatin, or pegylated liposomal doxorubicin.
J Orthop Trauma
April 2022
Department of Orthopaedics, Boston Medical Center, Boston, MA.
Objectives: To report functional outcomes of unilateral sacral fractures treated both operatively and nonoperatively.
Design: Prospective, multicenter, observational study.
Setting: Sixteen Level 1 trauma centers.
Gynecol Oncol Rep
August 2021
The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Objectives: To determine whether previously undetected occult micrometastasis (MM) or isolated tumor cells (ITC) is associated with increased recurrence odds in stage I-II endometrioid adenocarcinoma.
Methods: Women with recurrent stage I/II EC who had complete pelvic and para-aortic were identified as the outcome of interest. A case-control study was designed with the exposure defined as occult MM/ITC not seen on original nodal pathology.
J Thromb Haemost
September 2021
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, Oklahoma, USA.
Background: A substantial proportion of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop severe/critical coronavirus disease 2019 (COVID-19) characterized by acute respiratory distress syndrome (ARDS) with thrombosis.
Objectives: We tested the hypothesis that SARS-CoV-2--induced upregulation of tissue factor (TF) expression may be responsible for thrombus formation in COVID-19.
Methods: We compared autopsy lung tissues from 11 patients with COVID-19--associated ARDS with samples from 6 patients with ARDS from other causes (non-COVID-19 ARDS) and 11 normal control lungs.
Ann Oncol
August 2021
Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Pharmacology, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), Caen, France. Electronic address:
Neoplasia
June 2021
Center for Cancer Prevention and Drug Development, Hem-Onc, Department of Medicine, Stephenson Cancer Center, University of Oklahoma HSC, Oklahoma City, OK, USA; VA Medical Center, Oklahoma City, OK, USA. Electronic address:
Lung cancer is the leading cause of cancer related deaths worldwide. The present study investigated the effects of naproxen (NSAID) on lung adenocarcinoma in spontaneous lung cancer mouse model. Six-week-old transgenic Kras mice (n = 20; male + female) were fed modified AIN-76A diets containing naproxen (0/400 ppm) for 30 wk and euthanized at 36 wk of age.
View Article and Find Full Text PDFPharm Res
May 2021
Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, 1 Medical Center Drive, Morgantown, West Virginia, 26506, USA.
Purpose: Therapeutic strategies to treat ischemic stroke are limited due to the heterogeneity of cerebral ischemic injury and the mechanisms that contribute to the cell death. Since oxidative stress is one of the primary mechanisms that cause brain injury post-stroke, we hypothesized that therapeutic targets that modulate mitochondrial function could protect against reperfusion-injury after cerebral ischemia, with the focus here on a mitochondrial protein, mitoNEET, that modulates cellular bioenergetics.
Method: In this study, we evaluated the pharmacology of the mitoNEET ligand NL-1 in an in vivo therapeutic role for NL-1 in a C57Bl/6 murine model of ischemic stroke.
Radiol Case Rep
June 2021
Department of Interventional Radiology, University of Oklahoma HSC, Oklahoma, OK 73104, USA.
We report a case of a 26-year-old male who was diagnosed with metastatic desmoplastic small round cell tumor initially treated with systemic chemotherapy followed by tumor debulking and hyperthermic intra-peritoneal chemotherapy. The patient was in complete remission by clinical and imaging criteria for 11 months, until he developed bi-lobar hepatic disease, which was successfully treated with selective internal radiation therapy by Yttrium-90. The patient demonstrated liver-specific complete response on follow-up imaging obtained 18 months after the procedure.
View Article and Find Full Text PDFGynecol Oncol Rep
February 2021
The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, United States.
The objective of this study was to describe the treatment experience of patients with recurrent epithelial ovarian cancer who are retreated with an inhibitor of poly(ADP-ribose)-polymerase (PARPi). We conducted a multi-institutional, retrospective review of ovarian cancer patients who received ≥2 lines of therapy containing a PARPi. Demographic, clinical, and pathological data were analyzed with descriptive statistics.
View Article and Find Full Text PDF